GLPwatch
[Emerging GLP-1 analogues and dipeptidyl peptidase 4(DPP-4) inhibitors].
Nihon Rinsho · 2011
Last updated 2026-05-28Newer versions of GLP-1 drugs and DPP-4 inhibitors are being developed for diabetes treatment. Currently, GLP-1 drugs like liraglutide and exenatide are used, but long-acting versions requiring only weekly or monthly injections have shown positive results. Additionally, new DPP-4 inhibitors are expected to join existing ones such as sitagliptin, vildagliptin, and alogliptin.
AI summary of the abstract below.
| Journal | Nihon Rinsho, 2011 |
|---|---|
| Citations | 0 |
| Relative citation ratio | 0.00 |
| NIH percentile | 0 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Obesity, Cardiovascular Risk Reduction, Chronic Kidney Disease |
Abstract
In recent years new antidiabetic medications utilizing incretin effects came to clinical practice, and enthusiasm surrounding this class of drugs has been mounting for their clinical efficacy as well as expected beneficial effects beyond lowering blood glucose levels. New DPP-4 inhibitors are expected to be available soon in addition to currently available DPP-4 inhibitors, sitagliptin, vildagliptin, and alogliptin. GLP-1 analogues, presently liraglutide and exenatide in clinical use, will also see newer alternatives in coming years. Long-acting GLP-1 analogues, which only require weekly or monthly injection, have also been developed, and their favorable clinical results have been reported. In this review, those newly developing DPP-4 inhibitors and GLP-1 analogues and their clinical efficacy are described.
Verbatim abstract via PubMed 21595278 ↗